Allergen Immunotherapy
Research activity is centered on subcutaneous immunotherapy for allergic rhinitis and allergic rhinoconjunctivitis, including patients with associated controlled allergic asthma. The sponsor focuses on treatment approaches targeting sensitization to specific allergens.
- Dermatophagoides pteronyssinus allergen components
- Der p 1, Der p 2, and Der p 23
- Cup a 1 immunotherapy
These studies reflect a strong interest in allergen-specific treatment for respiratory allergy conditions driven by defined sensitization profiles.
Mite Allergy and Respiratory Sensitization
The sponsor also investigates mite-related allergy across several clinically relevant species, with attention to patients sensitized to Dermatophagoides and other household or environmental mites.
- Dermatophagoides farinae
- Blomia tropicalis
- Lepidoglyphus destructor
This area includes work on allergic disease linked to airborne mite exposure and the characterization of reactions in sensitized individuals.
Allergen Extract Standardisation
A further area of interest is the biological standardisation of allergenic extracts, with emphasis on defining biological activity in sensitized patients and aligning extract potency with measurable skin reactivity.
- Biological units
- Hep units
- Histamine-based reactivity assessment
These studies support the development and characterization of diagnostic and therapeutic allergen preparations used in clinical allergy care.
